Patient Name : Mr.

AMANPREET SINGH Collected : 25/Oct/2025 11:21AM

Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:53PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 01:59PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF HAEMATOLOGY

Test Name Result Unit Bio. Ref. Interval Method

COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD EDTA
HAEMOGLOBIN 14.5 g/dL 13-17 CYANIDE FREE
COLOUROMETER
PCV 42.10 % 40-50 PULSE HEIGHT AVERAGE
RBC COUNT 5.2 Million/[Link] 4.5-5.5 Electrical Impedence
MCV 81 fL 83-101 Calculated
MCH 27.9 pg 27-32 Calculated
MCHC 34.4 g/dL 31.5-34.5 Calculated
R.D.W 15.7 % 11.6-14 Calculated
TOTAL LEUCOCYTE COUNT (TLC) 6,250 cells/[Link] 4000-10000 Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)
NEUTROPHILS 49 % 40-80 Electrical Impedance
LYMPHOCYTES 40 % 20-40 Electrical Impedance
EOSINOPHILS 05 % 1-6 Electrical Impedance
MONOCYTES 06 % 2-10 Electrical Impedance
BASOPHILS 00 % <1-2 Electrical Impedance
CORRECTED TLC 6,250 Cells/[Link] Calculated
ABSOLUTE LEUCOCYTE COUNT
NEUTROPHILS 3062.5 Cells/[Link] 2000-7000 Calculated
LYMPHOCYTES 2500 Cells/[Link] 1000-3000 Calculated
EOSINOPHILS 312.5 Cells/[Link] 20-500 Calculated
MONOCYTES 375 Cells/[Link] 200-1000 Calculated
Neutrophil lymphocyte ratio (NLR) 1.23 0.78- 3.53 Calculated
PLATELET COUNT 250000 cells/[Link] 150000-410000 IMPEDENCE/MICROSCOPY
MPV 8 Fl 8.1-13.9 Calculated

Page 1 of 8

SIN No:HA09966408
Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 04:57PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 06:37PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA
HBA1C, GLYCATED HEMOGLOBIN 5.9 % HPLC
ESTIMATED AVERAGE GLUCOSE 123 mg/dL Calculated
(eAG)

Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:
Reference Group HbA1c (%) HbA1c (mmol/mol)
Non-Diabetic <5.7 <38.8
Prediabetes 5.7 – 6.4 38.8 – 46.5
Diabetes ≥ 6.5 ≥47.5

Diabetics

Excellent control 6–7 42.1 – 53.0

Fair to good control 7–8 53.0 – 63.9
Unsatisfactory control 8 – 10 63.9 – 85.8
Poor control >10 >85.8
Note: HbA1c IFCC (mmol/mol) = (10.93 x HbA1c NGSP (%)) – 23.50
1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
Control by American Diabetes Association guidelines 2023.
2. Trends in HbA1c values is a better indicator of Glycemic control than a single test.
3. Low HbA1c in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control
when clinical conditions that affect erythrocyte survival are present.
5. In cases of Interference from Haemoglobin variants (HbF >25%, Homozygous Hemoglobinopathies) in HbA1C testing, alternative methods (Fructosamine) estimation is recommended for Glycemic Control.
Abnormal Haemoglobin studies (HPLC/Electrophoresis) is recommended for detection of Hemoglobinopathies.

Page 2 of 8

SIN No:BI28588478
Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:53PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 03:43PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

LIPID PROFILE , SERUM
TOTAL CHOLESTEROL 264 mg/dl 0-200 CHOD
TRIGLYCERIDES 78 mg/dl 0-150 GPO, Trinder
HDL CHOLESTEROL 52 mg/dL 40-60 CHOD
NON-HDL CHOLESTEROL 212 mg/dL <130 Calculated
LDL CHOLESTEROL 195.98 mg/dL <100 Calculated
VLDL CHOLESTEROL 15.62 mg/dL <30 Calculated
CHOL / HDL RATIO 5.05 0-4.97 Calculated
ATHEROGENIC INDEX (AIP) 0.01 <0.11 Calculated

Comment:
Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.
Below Table as per Lipid Association of India (LAI) (2023) and Cardiological Society of India (CSI) (2024) Guidelines and Consensus Statements for Dyslipidemia Management:
Low Risk Moderate Risk High Risk Very High Risk Extremely High Risk
Total Cholesterol < 200 < 200 200 – 239 ≥ 240 ≥ 240
Triglycerides <150 < 150 150 – 199 200 – 499 ≥ 500
≥ 190
Target for Extreme Risk –
130 – 159 160 – 189 Category A,B :< 30,Category C: 10 – 15
LDL < 100 100 – 129 Target for High Target for Very High
Risk: < 70 Risk: < 50

HDL ≥ 60 ≥ 60 M: <40, F: <50 <30 <30

160-189 190 – 219 ≥220
Non-HDL Cholesterol < 130 130 – 159 Target for High Target for Very High Target for Extreme Risk –
Risk: < 100 Risk: < 80 Category A,B :< 60, Category C: 40 – 45

Note: Low risk – No known risk factor of cardiovascular disease. Moderate risk – Any one risk factor, eg; smoking/hypertension/diabetes mellitus etc. High risk – Two or more risk factors
without any disease manifestation, chronic kidney disease, long-standing diabetes mellitus existing for >10 years, history of heterozygous familial hypercholesterolemia.
Very high risk – clinical evidence of coronary artery disease, long-standing diabetes mellitus existing for >20 years, etc. Extremely high risk – recurrent vascular events.
(Category A- CAD with >1 feature of High risk group, Category B- CAD with >1 feature of very high risk group or poly-vascular disease, Category C- Recurrent CAD with
other significant risk factors as high lipoprotein a, extensive coronary calcium)
1. Measurements for Lipids (Especially Triglycerides) can show physiological (Dependent on diet,10-12 hrs fasting pre-test condition) & analytical variations.
2. Lipid Association of India (LAI) recommends screening of all adults (>20 yrs) for Atherosclerotic Cardiovascular Disease (ASCVD) risk factors with lipid profile testing.
The association recommends testing also to include Apolipoprotein B & Lipoprotein (a) for stratification and defining LDL – C targets.

Page 3 of 8

SIN No:BI28588477
Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:53PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 03:43PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

LIVER FUNCTION TEST (LFT) WITH GGT , SERUM
BILIRUBIN, TOTAL 0.30 mg/dL 0-1.2 NBD
BILIRUBIN CONJUGATED (DIRECT) 0.13 mg/dl 0-0.2 Diazotized sulfanilic
acid
BILIRUBIN (INDIRECT) 0.17 mg/dL 0.0-1.1 Calculated
ALANINE AMINOTRANSFERASE 17.46 U/I 0-45 IFCC
(ALT/SGPT)
ASPARTATE AMINOTRANSFERASE 21.4 U/I 0-35 IFCC
(AST/SGOT)
AST (SGOT) / ALT (SGPT) RATIO (DE 1.2 <1.15 Calculated
RITIS)
ALKALINE PHOSPHATASE 66.00 U/I 53-128 IFCC (AMP buffer)
PROTEIN, TOTAL 8.02 g/dl 6.4-8.3 Biuret
ALBUMIN 4.92 g/dl 3.5-5.2 Bromcresol Green
GLOBULIN 3.10 g/dL 2.0-3.5 Calculated
A/G RATIO 1.59 0.9-2.0 Calculated
GAMMA GLUTAMYL 24.21 U/I 0-55 IFCC
TRANSPEPTIDASE (GGT)

Comment:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis
(Albumin) Common patterns seen:
1. Hepatocellular Injury: *AST – Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT – Elevated levels indicate hepatocellular
damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST:
ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons’s diseases, Cirrhosis,
but the increase is usually not >[Link]- If both SGPT and SGOT are within reference range then AST:ALT (De Ritis ratio) does not have any clinical significance.
2. Cholestatic Pattern:*ALP – Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.*Bilirubin (Direct) and GGT
elevated- helps to establish hepatic origin.
3. Synthetic function impairment:*Albumin- Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
4. Associated tests for assessment of liver fibrosis - Fibrosis-4 and APRI Index.

Page 4 of 8

SIN No:BI28588477
Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:53PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 03:43PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM
CREATININE 0.87 mg/dL 0.67-1.17 Enzymatic colorimetric
.eGFR - ESTIMATED GLOMERULAR 110.25 mL/min/1.73m² >60 CKD-EPI FORMULA
FILTRATION RATE
UREA 39.30 mg/dl 13-43 Urease, UV
BLOOD UREA NITROGEN 18.4 mg/dL 8.0 - 23.0 Calculated
URIC ACID 4.07 mg/dL 3.5-7.2 Uricase
CALCIUM 9.85 mg/dl 8.6-10.3 Arsenazo III
PHOSPHORUS, INORGANIC 3.45 mg/dl 2.7-4.5 Molybdate
SODIUM 140 mmol/L 135-145 Direct ISE
POTASSIUM 4.0 mmol/L 3.5-5.1 ISE (Indirect)
CHLORIDE 104 mmol/L 98 - 107 Direct ISE
PROTEIN, TOTAL 8.02 g/dl 6.4-8.3 Biuret
ALBUMIN 4.92 g/dl 3.5-5.2 Bromcresol Green
GLOBULIN 3.10 g/dL 2.0-3.5 Calculated
A/G RATIO 1.59 0.9-2.0 Calculated

Page 5 of 8

SIN No:BI28588477
Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:53PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 02:40PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF IMMUNOLOGY

Test Name Result Unit Bio. Ref. Interval Method

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM
TRI-IODOTHYRONINE (T3, TOTAL) 91.305 ng/dL 80-190 CLIA
THYROXINE (T4, TOTAL) 7.22 µg/dL 5-13 CLIA
TSH (Ultrasensitive/4thGen) 2.177 µIU/mL 0.35-4.75 CLIA

Comment:
For pregnant females Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester 0.1 - 2.5
Second trimester 0.2 – 3.0
Third trimester 0.3 – 3.0

1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) & its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit

production of TSH.

2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or

hyperthyroidism respectively.

3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is

free and biologically active. Isolated low T3 is often noticed in elderly

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH T3 T4 FT4 Possible Suggested Conditions correlating with pattern

High Low Low Low Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis

High N N N Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.

N/Low Low Low Low Secondary and Tertiary Hypothyroidism
Low High High High Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low N N N Subclinical Hyperthyroidism
Low Low Low Low Central Hypothyroidism, Treatment with Hyperthyroidism
Low N High High Thyroiditis, Interfering Antibodies
N/Low High N N T3 Thyrotoxicosis, Non thyroidal causes
High High High High Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 6 of 8

SIN No:IM10712779
Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:53PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 02:40PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF IMMUNOLOGY

Test Name Result Unit Bio. Ref. Interval Method

VITAMIN D (25 - OH VITAMIN D) , 14.053 ng/mL 30-100 CLIA
SERUM

Comment:
BIOLOGICAL REFERENCE RANGES
VITAMIN D STATUS VITAMIN D 25 HYDROXY (ng/mL)
DEFICIENCY <10
INSUFFICIENCY 10 – 30
SUFFICIENCY 30 – 100
TOXICITY >100

The biological function of Vitamin D is to maintain normal levels of calcium and phosphorus absorption. 25-Hydroxy vitamin D is
the storage form of vitamin D. Vitamin D assists in maintaining bone health by facilitating calcium absorption. Vitamin D deficiency
can also cause osteomalacia, which frequently affects elderly patients.
Vitamin D Total levels are composed of two components namely 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 both of
which are converted into active forms. Vitamin D2 level corresponds with the exogenous dietary intake of Vitamin D rich foods as
well as supplements. Vitamin D3 level corresponds with endogenous production as well as exogenous diet and supplements.
Vitamin D from sunshine on the skin or from dietary intake is converted predominantly by the liver into 25-hydroxy vitamin D,
which has a long half-life and is stored in the adipose tissue. The metabolically active form of vitamin D, 1,25-di-hydroxy vitamin
D, which has a short life, is then synthesized in the kidney as needed from circulating 25-hydroxy vitamin D. The reference interval
of greater than 30 ng/mL is a target value established by the Endocrine Society.
Decreased Levels:- Inadequate exposure to sunlight, Dietary deficiency, Vitamin D malabsorption, Severe Hepatocellular
disease., Drugs like Anticonvulsants, Nephrotic syndrome.
Increased levels:- Vitamin D intoxication.

Page 7 of 8

SIN No:IM10712779
Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:59PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 03:43PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Unit Bio. Ref. Interval Method

COMPLETE URINE EXAMINATION (CUE) , URINE
Physical Examination
COLOUR PALE YELLOW PALE YELLOW Visual
TRANSPARENCY CLEAR CLEAR Physical Measurement
pH 6.00 5-7.5 Double Indicator
SP. GRAVITY 1.025 1.002-1.030 Bromothymol Blue
BIOCHEMICAL EXAMINATION
URINE PROTEIN NEGATIVE NEGATIVE Protein Error of
Indicator
GLUCOSE NEGATIVE NEGATIVE Glucose Oxidase
URINE BILIRUBIN NEGATIVE NEGATIVE Azo Coupling Reaction
URINE KETONES (RANDOM) NEGATIVE NEGATIVE Sodium Nitro Prusside
UROBILINOGEN Normal NORMAL Modifed Ehrlich
Reaction
NITRITE NEGATIVE NEGATIVE Diazotization
LEUCOCYTE ESTERASE NEGATIVE NEGATIVE Leucocyte Esterase
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY
Pus Cells 0-1 /hpf 0-5 Microscopy
EPITHELIAL CELLS 0-1 /hpf <10 Microscopy
RBC NIL /hpf 0-2 Microscopy
CASTS NIL 0-2 Hyaline Cast Microscopy
CRYSTALS ABSENT ABSENT Microscopy

Comment:
All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods.
Microscopy findings are reported as an average of 10 high power fields.

*** End Of Report ***

Page 8 of 8

SIN No:C04092755
 Patient Name : [Link] SINGH Collected : 25/Oct/2025 11:21AM
Age/Gender : 37 Y 0 M 0 D /M Received : 25/Oct/2025 12:59PM
UHID/MR No : DBQT.0000000138 Reported : 25/Oct/2025 03:43PM
Visit ID : DBQTOPV616 Status : Final Report
Ref Doctor : [Link] Client Name : PCC BHARETT BIOTECH
IP/OP NO : Center location : JAIL ROAD,West Delhi

TERMS AND CONDITIONS GOVERNING THIS REPORT

1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understand
reporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever
2. This is computer generated medical diagnostics report that has been validated by an Authorized Medical Practitioner/Doctor. The
report does not need physical signature.
3. Partial reproduction of this report is not valid and should not be resorted to draw any conclusion.
4. In the case you are not the intended recipient of this report. Please immediately return the same to the concerned issuing desk. Any
disclosure, copy or distribution of any contents of this report, is unlawful and is strictly prohibited.
5. Results delays may occur due to unforeseen circumstances such as non-availability of kits, equipment breakdown, natural calamities,
IT downtime, logistic delays or any other unavoidable event. For certain tests based on analyte stability, criticality of results and in the
interest of patient for having appropriate medical diagnosis, the same test may be outsourced to other accredited laboratory.
6. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of
particulars have been confirmed by the patient or his / her representative at the point of generation of said specimen
7. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient (within subject biological variation).
8. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be
communicated to the assigned regulatory bodies
9. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
the laboratory.
10. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only

SIN No:C04092755